Non-Hispanic Black patients are less likely to receive guideline-appropriate treatment for ovarian cancer than non-Hispanic White patients, significantly affecting their treatment quality and survival chances.
The study, appearing online in the Journal of the National Comprehensive Cancer Network, was led by Duke Health researchers Mary Katherine Montes De Oca, MD, a resident in Duke’s Department of Obstetrics and Gynecology, and Tomi Akinyemiju, PhD, associate professor in the Department of Population Health Sciences.
The researchers focused on whether there were any racial differences in the application of guidelines among women with ovarian cancer. The guidelines specify treatment standards such as performing surgeries to assess cancer stage or administering the appropriate number of chemotherapy cycles.
More than 6,600 Medicare patients with ovarian cancer were analyzed from a database. Of those, 23.8% of White patients received guideline-appropriate surgery and chemotherapy compared to 14.2% of Black patients.